GoKawiilNature study: GLP-1 obesity drug extended lifespan in older female mice
Researchers publishing in Nature on September 2 found that older female mice given a GLP-1 obesity drug lived longer than untreated mice and showed slower onset of several biological markers linked to aging. The finding builds on earlier mouse studies suggesting GLP-1 medications, typically used for obesity and type 2 diabetes, may have broader anti-aging effects beyond weight loss.
GoKawiil's interpretation of the reporting above, not reported fact.
GLP-1 drugs like semaglutide have already expanded far beyond diabetes and obesity treatment, and if they genuinely slow biological aging, they could become one of the first widely available longevity therapies. However, the results so far are confined to mice, and scientists caution that proving similar effects in humans through clinical trials could take years.
- Older female mice on a GLP-1 drug lived longer and showed delayed aging markers, per new Nature research.
- Scientists are investigating whether reduced calorie intake from appetite suppression drives the longevity effect.
- Human clinical trials are underway, but experts call the animal findings preliminary and early-stage.
Source: nature.com — Lenharo, 2026-09-02
Published there as: “Can GLP-1 drugs slow ageing? Mouse study shows promise”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.